A phase II/III, open-label study of the pharmacokinetics, safety, and antiviral activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected antiretroviral treatment-naive adolescents

Project no.: HIV-NAT 190/GS-US-292-0106 (NCT01854775)

This is an open-label, multicenter, two-part, single-arm study of the pharmacokinetics, safety, tolerability, and antiviral activity of the single tablet regimen (STR)elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV 1 infected, ARV treatment naive adolescents determined by the achievement of HIV-1 RNA < 50 copies/mL Weeks 24 and 48 as defined by the FDA snapshot analysis.